What does this mean? Researchers have found that a genomic variant in a single nucleotide polymorphism (SNP) called rs11672691 influences prostate cancer aggressiveness. Genome-wide association studies (GWAS) also identified ways to improve risk stratification and clinical treatment for advanced prostate cancer.
The study “Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus” has been published in the journal Cell.
“How human genomic variants cause disease and its progression is in general one of the most compelling puzzles and questions in medicine,” says Academy Research Fellow Gong-Hong Wei at Biocenter Oulu in the University of Oulu.
The rs11672691(G) increase the transcript levels of PCAT19 and CEACAM21, two proteins associated with cell growth and tumor progression. In 2014, the National Cancer Institute Breast and Prostate Cancer Cohort Consortium have made a study to examine the association of 47 established PCa risk single-nucleotide polymorphisms (SNPs) with PCa-specific mortality (PCSM). Thet included 10 487 men who had PCa and 11 024 controls, with a median follow-up of 8.3 yr, during which 1053 PCa deaths occurred. Eight were associated with progression to PCSM after diagnosis. Twenty-two SNPs were associated with fatal PCa incidence, but most did not differentiate between fatal and nonfatal PCa. However, larger studies that focus on fatal PCa are needed to identify more markers that could aid prediction.
In July 2018, researchers at the University of Oulu in Finland describe how they investigated a genomic variant known to be linked to aggressive prostate cancer. The genomic variant is a difference in a DNA building block located in chromosome 19q13 that is known as the single nucleotide polymorphism (SNPs) rs11672691. 2,738 cases of prostate cancer were analyzed. Using “genetic, genomic, molecular, and bioinformatic” tools, the team confirmed that the rs11672691 variant makes prostate cancer become aggressive. After a thorough investigation, Prof. Wei and his multinational collaborators conclude also that the guanine allele of rs11672691 influences a third gene called HOXA2. This gene contains the instructions for producing a protein that controls the decoding of PCAT19 and CEACAM21.
“We think the findings may be repurposed to stratify prostate cancer patients for personalized treatment and care. But how this gene regulatory circuit accounts for pathogenesis and progression of prostate cancer warrants further investigation,” added Prof. Gong-Hong Wei.
The PSA test helps to detect prostate cancer. Making this decision depends on a variety of factors, but it’s better to prevent this problem than to deal directly with it. The American Cancer Society recommends that men ages 55 to 69 discuss the benefits and risks of prostate cancer screening with their doctors. Different tests are available which can give you the right information about the tumors growth rate, aggressiveness, and risk of morbidity.
Here’s more information about the PSA tests to help you in the decision!
- The prostate health index – PHI test –is a combination of three forms of the PSA protein. The results are used to provide a probability of cancer.
- The 4k scoreis a blood test measuring four different prostate related proteins that provides a percent risk score of having an aggressive prostate cancer.
- The prostate cancer gene 3 test -PCA 3 –is a gene-based test carried out on urine: higher the level, the more likely the chance cancer is present.
- The prostate can be evaluated further with the Uro/NAV MR/Ultrasound fusion biopsy system. Fusion biopsy is a more effective method for detecting and diagnosing high-risk and aggressive prostate cancers.
For any questions that men may have regarding the prostate cancer, you can contact Dr. David Samadi and set up an appointment. Don’t hesitate! Your health is a priority! Your happiness is essential! Your self-care is a necessity!